Clinical Research Currents
  • Home
  • About Us
  • News
    • AI & Machine Learning
    • Alzheimers & Dementia
    • Animal studies
    • Clinical development
    • Clinical science
    • Contract Research Organization
    • Disparities
    • Education
    • Employment
    • FDA
    • FDA Guidance
    • FDA Guidance Documents
    • History
    • Immunotherapy
    • Innovation
    • International
    • Interview
    • Investigator
    • Mobile
    • NIH
    • Operations
    • Patient Perspective
    • Political economy
    • Pre-clinical
    • Precision Medicine
    • Recruitment
    • Regulatory
    • Study Design
    • Wearables
    • Trends
    • Real World Data/Evidence
    • Blockchain
    • Clinical trials
    • Adverse events
    • Technology
  • Calendar
  • Newsletter
  • Resources

2021 Update

Clinical Research Currents has temporarily suspended publication.
Learn about our new clinical trials startup, Sparrow Search, connecting patients with clinical trials.

Drug sponge could minimize side effects of cancer treatment

www.sciencedaily.com

February 18, 2019
Adverse events, Oncology

Catheters are used today to deliver drugs directly to tumors, but half of the drug can still escape to the rest of the body, causing side effects. Doctors treating liver cancer worked with chemical engineers to design an absorbent polymer-coated device that can be temporarily placed in the vein coming out of the liver to absorb unused chemotherapy drugs, potentially lowering the risk of side effects. (Science Daily)

Only 10% of those harmed in clinical trials in India receive compensation

www.pharmafile.com

February 2, 2019
Adverse events, Clinical trials, International

Since 2005, nearly 17,000 clinical drug trials were conducted in India. It is estimated that nearly 5,000 people lost their lives in clinical trials in India, and hundreds developed serious side effects, but only 10% of those affected received compensation. (Pharmafile)

Clinical trials underestimate adverse events associated with immunotherapies

www.specialtypharmacytimes.com

December 7, 2018
Adverse events, Clinical trials, Oncology

An analysis of adverse events (AEs) associated with immune checkpoint inhibitors based on insurance claims suggests that the frequencies of immune-related AEs may be higher than reported in trials that led to the FDA approvals for immunotherapies. The researchers suggest that real world data could refine our expectations for outcomes beyond what is reported in clinical trials. (Specialty Pharma Times)

Subscribe to our Newsletter

Get the latest clinical research news delivered straight to your inbox each week.

Submit a Story

Do you have a story you'd like to feature on our website? Share it with us today!

Submit your story

 Join our LinkedIn Group

© 2023 Clinical Research Currents · All Rights Reserved